Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 655-668

  Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD20; ibritumomab tiuxetan (Zevalin ); NHL; radioimmunoconjugate; radioimmunotherapy; tositumomab (Bexxar )

Indexed keywords

ALKYLATING AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GROWTH FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOSTIMULATING AGENT; MELPHALAN; METHOTREXATE; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; THYROID HORMONE; TOSITUMOMAB I 131; VINCRISTINE SULFATE;

ACUTE LEUKEMIA; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DOSIMETRY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GAMMA RADIATION; HUMAN; HYPOTHYROIDISM; IMMUNOTOXICITY; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RETREATMENT; REVIEW; SECOND CANCER; SINGLE DRUG DOSE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 33748713431     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.05.002     Document Type: Review

References (59)

1. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16 (1998) 2825-2833
2. Witzig T.E., Vukov A.M., Habermann T.M., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology 23 (2005) 1103-1108
3. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
4. Hochster H.S., Weller E., Gascoyne R., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 11 (2005) 349
5. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
6. Van Oers M.H.J., Glabbeke M.V., Tzeodorovic I., et al. Chimeric anti-CD20 monoclonal antibody (Rituximab;Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized intergroup clinical trial. Session Type: Oral Session. Blood 106 (2005) [Abstract 353]
7. Mounier N., Briere J., Gisselbrecht C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
8. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine 346 (2002) 235-242
9. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lympoma. Journal of Clinical Oncology 24 19 (2006) 3121-3127
10. Skvortsova I., Popper B.A., Skvortsov S., et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. Journal of Radiation Research 46 (2005) 241-248
11. Dillman R.O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. Journal of Clinical Oncology 20 (2002) 3545-3557
12. Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101 (2003) 391-398
13. Fisher R.I., LeBlanc M., Press O.W., et al. New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology 23 (2005) 8447-8452
14. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Journal of Nuclear Medicine 44 (2003) 465-474
15. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 17 (1999) 3793-3803
16. Wahl R.L., Zasadny K.R., MacFarlane D., et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. Journal of Nuclear Medicine 39 (1998) 21S-27S
17. Wahl R.L., Kroll S., and Zasadny K.R. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. Journal of Nuclear Medicine 39 (1998) 14S-20S
18. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine 329 (1993) 459-465
19. Wahl R.L. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. Journal of Nuclear Medicine 39 (1998) 1S
20. Koral K.F., Dewaraja Y., Li J., et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. Journal of Nuclear Medicine 44 (2003) 457-464
21. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research 2 (1996) 457-470
22. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology 14 (1996) 1974-1981
23. Stagg R., Wahl R.L., Estes J., et al. Phase I/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): final results. Proceedings of the American Society of Clinical Oncology 17 (1998) 39a [Abstract 150]
24. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Journal of Clinical Oncology 21 (2003) 1263-1270
25. Fehrenbacher L., Radford J.A., Kaminski M., et al. Patient-specific dosing of Bexxar™ is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors. Proceedings of the American Society of Clinical Oncology 20 (2001) 287a [Abstract 1144]
26. Wiseman G.A., Gordon L.I., Multani P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99 (2002) 4336-4342
27. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology 18 (2000) 1316-1323
28. 131I-tositumomab therapy as initial treatment for follicular lymphoma. The New England Journal of Medicine 352 (2005) 441-449
29. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology 19 (2001) 3918-3928
30. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (2005) 4576-4582
31. Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 4 (1986) 1470-1480
32. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of 90Y-labeled ibritumomab tiuxetan (zevalin) radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 20 (2002) 2453-2463
33. Cheson B., Horning S., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. Journal of Clinical Oncology 17 (1999) 1244-1253
34. Davis T.A., Kaminski M.S., Leonard J.P., et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical Cancer Research 10 (2004) 7792-7798
35. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology 20 (2002) 3262-3269
36. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Journal of Clinical Oncology 23 (2005) 712-719
37. Wiseman G.A., and Witzig T.E. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biotherapy & Radiopharmaceuticals 20 (2005) 185-188
38. Fisher R.I., Kaminski M.S., Wahl R.L., et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of Clinical Oncology 23 (2005) 7565-7573
39. Gordon L.I., Molina A., Witzig T., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103 (2004) 4429-4431
40. Morschhauser F., Huglo D., Martinelli G., et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 110 (2004) [Abstract 130]
41. ®]. Blood 100 (2002) [Abstract]
42. ®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104 (2004) 2632 [Abstract]
43. Ansell S.M., Ristow K.M., Habermann T.M., et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Journal of Clinical Oncology 20 (2002) 3885-3890
44. Ansell S.M., Schilder R.J., Pieslor P.C., et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clinical Lymphoma 5 (2004) 202-204
45. Cooney J., Stiff P., and Kaminski M. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Bone Marrow Transplantation 29 (2002) 523-525
46. Dosik A.D., Coleman M., Kostakoglu L., et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106 (2006) 616-622
47. Kaminski M.S., Radford J.A., Gregory S.A., et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology 23 (2005) 7985-7993
48. Wiseman G., Colgan J., Inwards D., et al. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results. Blood 100 (2002) 358a [Abstract 1387]
49. Wiseman G., and Witzig T. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results. Blood 100 (2002) 358a [Abstract 1387]
50. Leonard J.P., Coleman M., Kostakoglu L., et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of Clinical Oncology 23 (2005) 5696-5704
51. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. [see comments]. The New England Journal of Medicine 329 (1993) 1219-1224
52. Press O.W., Eary J.F., Appelbaum F.R., et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995) 336-340
53. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Journal of Clinical Oncology 16 (1998) 3270-3278
54. Press O., Eary J., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
55. Gopal A.K., Rajendran J.G., Petersdorf S.H., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 (2002) 3158-3162
56. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
57. Winter J.N. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clincal Lymphoma 5 (2004) S22-S26
58. Winter J.N., Inwards D., Erwin W., et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood 100 (2002) 411a [Abstract 1597]
59. Justice T., Martenson Jr. J.A., Wiseman G., et al. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer 107 2 (2006) 433-438